Publications (112) Publications in which a researcher has participated

2019

  1. A multifunctional drug nanocarrier for efficient anticancer therapy

    Journal of Controlled Release, Vol. 294, pp. 154-164

  2. A novel saliva-based mirna signature for colorectal cancer diagnosis

    Journal of Clinical Medicine, Vol. 8, Núm. 12

  3. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 121, Núm. 5, pp. 378-383

  4. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study

    Investigational New Drugs, Vol. 37, Núm. 1, pp. 98-108

  5. Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP)

    Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 380-390

  6. Analysis of the relationship between ratio N/L and survival in lung cancer patients treated with immunotherapy.

    Journal of Clinical Oncology, Vol. 37, Núm. 15_suppl, pp. e14247-e14247

  7. Are reactive C protein and procalcitonin useful for early diagnosis of postoperative intraabdominal infection after pancreaticoduodenectomy for pancreatic cancer?

    Cirugia y Cirujanos (English Edition), Vol. 87, Núm. 6, pp. 662-666

  8. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

  9. Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment

    Head and Neck, Vol. 41, Núm. 8, pp. 2704-2715

  10. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

    Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310

  11. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  12. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

    Journal of Patient-Reported Outcomes, Vol. 3, Núm. 1

  13. BRAF mutations classes I, II, and III in NSCLC patients included in the SLLIP trial: The need for a new pre-clinical treatment rationale

    Cancers, Vol. 11, Núm. 9

  14. Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists

    JOURNAL OF DRUG ASSESSMENT, Vol. 8, Núm. 1, pp. 62-69

  15. CTCs expression profiling for advanced breast cancer monitoring

    Cancers, Vol. 11, Núm. 12

  16. CTCs-derived xenograft development in a triple negative breast cancer case

    International Journal of Cancer, Vol. 144, Núm. 9, pp. 2254-2265

  17. Cancer associated fibroblasts: is the force the path to the dark side?

    Current Opinion in Cell Biology, Vol. 56, pp. 71-79

  18. Cancer cells in the tumor core exhibit spatially coordinated migration patterns

    Journal of Cell Science, Vol. 132, Núm. 6

  19. Cell-Free microRNAs as Potential Oral Cancer Biomarkers: From Diagnosis to Therapy

    Cells, Vol. 8, Núm. 12

  20. Characterization of HMGB1/2 interactome in prostate cancer by yeast two hybrid approach: Potential pathobiological implications

    Cancers, Vol. 11, Núm. 11